女性骨髓增殖性肿瘤的关注议题
本综述聚焦女性骨髓增殖性肿瘤(MPN)的性别差异,涵盖流行病学与诊断阈值、遗传特征与表型、血栓风险与结局、生育期与妊娠管理等方面。女性MPN总体患病率更高,诊断时更年轻,症状负荷评分更高,但疾病转化和总生存结局优于男性。综述还汇总了妊娠期阿司匹林和干扰素-α等管理推荐。
要点
- 女性MPN患病率高于男性,以原发性血小板增多症(ET)为主,真性红细胞增多症(PV)和骨髓纤维化(MF)频率低于男性。
- PV诊断阈值存在性别差异:女性血红蛋白>16.0 g/dL、血细胞比容>48%,男性分别为>16.5 g/dL和>49%。
- 女性MPN诊断时更年轻、症状负荷评分更高,但MF/白血病转化率和继发癌症率更低,总生存优于男性。
核心结论
- 性别是MPN发病率、临床表现和自然史的关键驱动因素,需以性别视角重新校准预后工具和临床试验设计。
- 女性MPN在多个生命周期阶段(青春期、孕前与生育、围绝经期)面临特殊挑战,包括口服避孕药和激素使用问题。
- 支持性别差异的若干机制已被阐明,但仍需进一步前瞻性研究。
研究设计与样本
- 综述,聚焦女性MPN的性别相关决定因素、生命周期窗口及妊娠管理。
主要发现
- 女性MPN总体患病率更高,ET发病占主导,PV和MF频率低于男性。
- 女性MPN获得性体细胞突变较少,高危突变频率低于男性,JAK2V617F驱动变异等位基因频率更低、等位基因负荷动力学减弱。
- 女性MPN诊断时比男性年轻,且依亚型不同表现更惰性;经过验证的症状负荷评估一致显示女性评分高于男性。
- 女性MPN血栓倾向独特,最终诊断为PV者更常累及内脏静脉系统。
- 女性性别与更有利的临床轨迹相关,包括MF/白血病转化率和继发癌症率更低,以及相对男性总生存率更优。
关键数值与推荐
- PV诊断阈值:女性血红蛋白>16.0 g/dL、血细胞比容>48%;男性血红蛋白>16.5 g/dL、血细胞比容>49%。
- 推荐所有患者每日阿司匹林81 mg。
- 推荐有既往血栓史者及低危但具更高危特征(如血细胞比容控制不佳和复发性胎儿丢失)者使用干扰素-α进行细胞减灭治疗。
- 推荐有既往静脉血栓栓塞史者产前使用低分子量肝素(LMWH)抗凝。
临床怎么用
- PV诊断应采用性别特异性血红蛋白和血细胞比容阈值。
- 妊娠期MPN管理采用基于产科和血栓史的风险适应策略:所有患者每日阿司匹林81 mg。
- 有既往血栓史或低危但具更高危特征者,推荐干扰素-α细胞减灭治疗。
- 有既往静脉血栓栓塞史者,产前推荐低分子量肝素抗凝。
局限性
- 支持性别差异的若干机制虽已阐明,但仍需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OVERVIEW: Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants. EPIDEMIOLOGY AND DIAGNOSIS: A higher overall prevalence of MPN has been established in women. The incidence of essential thrombocythemia (ET) predominates, while, conversely, polycythemia vera (PV) and myelofibrosis (MF) are seen in lower frequencies as compared to men. Diagnostic criteria are dictated by sex-driven physiological variances in hemoglobin and hematocrit levels in PV, mandating separate diagnostic thresholds, respectively: > 16.0 g/dL and > 48% in women vs. > 16.5 and > 49% in men. GENETIC FRAMEWORK AND PHENOTYPE: Women with MPN harbor fewer acquired somatic mutations and a lower frequency of high-risk mutations than their male counterparts; lower JAK2V617F driver variant allele frequency and attenuated allele burden kinetics have also been reported. Women with MPN are younger at diagnosis than men and, contingent on subtype, display more indolent disease features. Importantly, validated symptom burden assessments consistently disclose higher scores in women vs. men. THROMBOSIS AND OUTCOMES: Women with MPN have a unique thrombotic diathesis with respect to men, more frequently involving the splanchnic venous system in those ultimately diagnosed with PV. Outcomes data depict female sex as a variable associated with more favorable clinical trajectories, including lower rates of MF/leukemic transformation and secondary cancers, as well as improved overall survival rates vis-à-vis men. LIFE-CYCLE WINDOWS, PREGNANCY, AND POSTPARTUM: Potential challenges at each significant life stage will be addressed: puberty, preconception and fertility, and perimenopause; these include issues surrounding oral contraceptives and hormone use. Prospective studies suggest overall favorable maternal and fetal outcomes with pregnancy in women with MPN. Full details on risks and reported outcomes will be discussed, as well as a risk-adapted approach to management informed by obstetric and thrombosis history. Recommendations include aspirin 81 mg daily in all patients and cytoreduction with interferon-α in those with antecedent thrombosis, as well as in low-risk cases with higher-risk features (e.g., poorly controlled hematocrit and recurrent fetal loss). Antepartum anticoagulation with low molecular weight heparin (LMWH) is recommended in cases with previous venous thromboembolism. CONCLUSIONS AND FUTURE DIRECTIONS: This review highlights female sex and gender as critical drivers of MPN incidence, presentation, and natural history. It further outlines the impact and management of MPN as related to unique female reproductive phases. A sex-informed lens will be required in order to recalibrate current prognostic tools, a requisite to refining patient counselling and clinical decision-making in line with precision medicine. Moreover, while several mechanisms underpinning sex-defined discrepancies have been defined, these mandate further prospective study. Finally, sex and gender-based differences must be weighted in clinical trials with systematized procedures to correct participation imbalances in favor of sex and gender equity.
引用
- Szuber N, Guglielmelli P, Gangat N, et al. Topics of Interest in Women With Myeloproliferative Neoplasms. Am J Hematol. 2025. PMID: 40084464. doi:10.1002/ajh.27665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。